Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE<sup>®</sup> to Provide Two Distinct and Complementary Perspectives.

Minasian, Lori M; O'Mara, Ann; Mitchell, Sandra A

Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE^® to Provide Two Distinct and Complementary Perspectives.

Minasian, Lori M; O'Mara, Ann; Mitchell, Sandra A.

Affiliation

Minasian LM; Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
O'Mara A; Consultant, ICF, Fairfax, VA, USA.
Mitchell SA; Consultant to Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.

Patient Relat Outcome Meas ; 13: 249-258, 2022.

Article de En | MEDLINE | ID: mdl-36524232

Mots clés

PRO-CTCAE; Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events; cancer therapy; patient-reported outcomes; tolerability; toxicity

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Diagnostic_studies / Risk_factors_studies Aspects: Patient_preference Langue: En Journal: Patient Relat Outcome Meas Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google